Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
Official title: Dual-[Hypoxia+Proliferation] PET as a Predictive Biomarker in Recurrent Glioblastoma
Funded at Weill Medical Coll of Cornell Univ · NIH-11445726 · Data updated 2026-11-12
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 10, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $655,014 |
| NIH project number | 1R01CA308323-01A1 |
| Project ID | NIH-11445726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with recurrent glioblastoma eligible for surgery and planning for radiotherapy.
✕Less likely to help
Patients whose tumors do not show hypoxia or proliferative patterns on imaging or who are not undergoing surgery may see limited direct benefit.
What this research studies
This project aims to combine two PET tracers in one imaging session to visualize hypoxia and tumor cell proliferation in glioblastoma, helping doctors tailor surgery and radiotherapy. Patients with recurrent GBM will have pre-operative dual-[FMISO+FLT] PET imaging, followed by maximal safe tumor resection. The imaging data will inform how best to target treatment and potentially improve outcomes by addressing the tumor’s resistant microenvironment.
Why it matters
Potential benefit: If successful, this approach could improve how surgeons plan resections and how radiotherapy is delivered for recurrent GBM, potentially extending survival and quality of life.
How similar studies have gone: Dual-tracer PET imaging is a novel approach in this setting, with limited prior clinical use but promising rationale.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Nehmeh, Sadek — Weill Medical Coll of Cornell Univ
- Study coordinator: Nehmeh, Sadek
Related research
Other NIH-funded projects on the same topics.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Targeting Fatty Acid Metabolism to Fight Brain Cancer (GBM)
A new treatment approach uses a repurposed drug to cut off the energy supply of glioblastoma tumors in the brain.
-
Giving immune checkpoint therapy before surgery for recurrent glioblastoma
This research gives an immune checkpoint drug before surgery to people with recurrent glioblastoma to help the immune system attack the tumor.
-
Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
-
Using immune therapy before surgery for recurrent glioblastoma
This study is looking at how giving a special immune therapy before surgery can help patients with recurrent glioblastoma fight their tumors better, and it will compare the results to the usual treatments given after surgery.
-
Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.